Capital Point 2025: Profit Returned, but Monetization Is Still the Test

Company Overview

At first glance, Capital Point looks like another small listed investment shell with a long list of portfolio names and a lot of paper value. That is only part of the picture. In practice, this is a small public investment vehicle with 19 active holdings, mostly around life sciences, alongside a growing layer of listed securities, marketable securities and investment funds. It does not have one portfolio company that defines the whole story, and it does not have an operating engine that generates recurring cash. So the right question is not simply how much the portfolio is worth, but how much of it can actually turn into cash for shareholders without another round of marks, market support or realizations.

What is working now is clear enough. After a NIS 23.9 million net loss in 2024, the company finished 2025 with a NIS 7.3 million net profit and a NIS 7.24 million comprehensive profit. Investments in project companies and listed holdings rose to NIS 62.3 million, marketable securities jumped to NIS 38.5 million, and finance income rose to NIS 6.34 million. Nasus, one of the more visible holdings in the portfolio, also became a Nasdaq-listed company during the year and started to contribute not only value, but also advisory income to Capital Point.

What is still not clean is the quality of the engine. In 2025 the company recorded NIS 21.7 million of fair value gains on investments, against NIS 10.2 million of fair value losses on the expense side. That created a net contribution of NIS 11.55 million to the bottom line. Without that contribution, and without supportive capital markets, the picture would look very different. At the same time, cash and cash equivalents fell from NIS 37.7 million to NIS 25.9 million, and operating cash flow remained negative at NIS 6.2 million. That is the real bottleneck. Not an immediate cash shortage, but an ongoing dependence on turning value into realizations.

That is also why the stock is still read through a discount rather than through book equity. At the end of 2025 equity stood at NIS 124.3 million. On the April 3, 2026 market screen, at 50.2 agorot per share, the company was trading at roughly NIS 67 million, around half of book value. Put differently, the market is not arguing with the existence of an investment portfolio. It is arguing with liquidity, with the quality of the marks in that portfolio, and with Capital Point's ability to come back with real cash rather than just a higher NAV line.

Quick Economic Map

Another key point is portfolio structure. The top five positions, Aura, Nasus, Mivtach Shamir, ZIM and Airport City, account for roughly NIS 39.5 million out of a NIS 62.3 million investment portfolio. That means around 63% of the portfolio sits in five names. So this is not a portfolio that is so diversified it loses meaning, but it is also not a story with one single anchor holding that the market can lock onto.

Events And Triggers

The first trigger: Nasus moved from being an interesting private holding to a more visible anchor in the portfolio. On August 12, 2025, Nasus completed an IPO on Nasdaq of 1.25 million ordinary shares at $8 per share, implying a post-money valuation of roughly $72 million. Capital Point purchased 150 thousand shares in the offering for a total of $1.2 million, and after the IPO held about 6.3% of Nasus. In addition, as of August 7, 2025, Capital Point had a business development services agreement with Nasus running through the end of June 2026, with total consideration of $600 thousand. That matters because in 2025 Nasus was not only a source of value uplift, but also a source of advisory revenue, and the only holding for which the company explicitly flags a material valuation.

The second trigger: Exithera is no longer the drag it was in 2024, but it has not yet become an upside case that investors can underwrite either. In July 2024 Capital Point recognized roughly NIS 28 million of fair value loss after Exithera decided to stop operations. In September 2025 its main assets were sold to Cardenal, with potential contingent consideration of up to $15 million plus royalties. But as of year-end the company assessed the probability of meeting all milestones as low, and therefore recognized no income. That is optionality, not a thesis anchor.

The third trigger: management is signaling confidence, but it is doing so in a noisy environment. On December 28, 2025 the two co-CEOs, through their holding company, purchased 364,846 Capital Point shares on market. On the other hand, between October and December 2025 the company was also dealing with letters from RPS, an interested party, alleging the existence of a control group and challenging board appointments. The company rejected those claims, and at the time the financial statements were approved the parties were still in dialogue. That does not break the company, but in a business of this size governance noise is part of the screen.

The fourth trigger: there is also an older tail from the energy side that has not gone away. NewMed argued in November 2025 that Capital Point should bear around $919 thousand of abandonment costs relating to the Ofek Hadash license, and after the balance sheet date said it had paid Capital Point's share and would seek arbitration if the amount was not reimbursed. The company recorded no provision because its advisers believe the claim is more likely to be rejected, but from a market-reading perspective this is exactly the kind of item that investors do not like to see in a small investment company.

The important point is the mix of these events. Capital Point is entering 2026 with one new anchor that looks constructive, Nasus, one unrecognized option, Exithera, and two legacy tails, governance and the energy dispute. That is not chaos, but it is also not a company the market can read through one clean engine.

Efficiency, Profitability And Competition

The central point is that 2025 profit came back through the portfolio and through the capital markets, not through the creation of a new recurring earnings engine. Revenue totaled NIS 29.9 million. Of that, NIS 21.7 million came from fair value gains on investments, NIS 6.34 million from finance income, NIS 1.15 million from advisory income and only NIS 673 thousand from dividends. On the other side, expenses totaled NIS 22.6 million, including NIS 10.16 million of fair value losses, NIS 9.05 million of G&A and NIS 3.39 million of finance expense. In other words, the 2025 engine was the easing of negative marks and a friendlier market backdrop, not the emergence of a large new operating revenue stream.

That is exactly what the market is testing. If you strip out the net fair value effect of NIS 11.55 million, you are left with a company that still does not generate comfortable standalone profitability. That does not mean the profit is somehow fake. In an investment company, fair value changes and realizations are part of the business model. But it does mean that the quality of 2025 depends on supportive markets, on continued access to realizations, and on keeping enough of the book in liquid, visible positions.

Even inside the portfolio, the recovery was not broad-based. Aura is carried at NIS 10.9 million against historical cost of NIS 1.7 million. Nasus is carried at NIS 10.7 million against cost of NIS 5.4 million. Mivtach Shamir stands at NIS 6.3 million against NIS 2.2 million of cost. On the other hand, FDNA is carried at NIS 3.19 million against NIS 6.22 million of cost, EGM at NIS 1.99 million against NIS 3.88 million, Ossio at NIS 490 thousand against NIS 3.1 million, Intuition Robotics at NIS 482 thousand against NIS 4.24 million, and Contify at NIS 464 thousand against NIS 2.75 million. So 2025 was not a year in which the whole portfolio healed together. It was a year in which a handful of quoted or IPO-linked names covered for a long tail of older weak positions.

There is also a governance detail worth noticing. Each co-CEO received a bonus of about NIS 1.01 million in 2025 tied to realizations and dividends from investee companies. That is an incentive structure that aligns management with the right direction, real cash rather than just reported NAV. But it cuts both ways. It is constructive because it pushes the company toward monetization. It is constraining because it can also favor turnover and deals over patience with certain assets.

From a competition perspective, the company itself describes its competitors as venture capital funds, private equity funds, private investors and government-backed funding mechanisms. Its edge is flexibility, capital markets experience and the ability to assemble fast equity-plus-debt structures. The weakness is obvious as well, it does not have the balance sheet to compete on scale with large funds. So the real competitive question is not whether Capital Point can find investments, but whether it can stay funded and patient long enough for those investments to become realizations.

Cash Flow, Debt And Capital Structure

The relevant cash frame here is all-in cash flexibility. This is not an industrial company where maintenance capex is the key normalization debate. It is an investment company, so the important question is how much liquidity remains after actual investing activity, active portfolio management and all of the legacy obligations still sitting at the company level.

At first glance the cash line looks ugly, down from NIS 37.7 million to NIS 25.9 million. But that is again only a partial read. If you combine cash, short-term deposits and marketable securities, liquid market-facing resources actually edged up from NIS 68.8 million to NIS 69.7 million. If you also include investment funds, the managed financial asset pool reaches NIS 82.3 million. In other words, the company did not simply burn through its cushion. It moved part of that cushion out of cash and into a larger securities book.

Operating cash flow remained negative at NIS 6.23 million. That is not surprising because the company's core activity is portfolio ownership and value creation, not a recurring operating cash engine. Investment activity was also mixed rather than catastrophic. The company invested NIS 18.4 million in project companies and listed holdings, extended NIS 1.07 million of loans, and purchased NIS 22.9 million of marketable securities. Against that, it realized NIS 28.2 million of investments, sold NIS 6.55 million of securities and released NIS 3.5 million of deposits on a net basis. The bottom line in investing cash flow was a net use of NIS 4.1 million, not a collapse.

The other side of the picture is liabilities. Here it is important to separate accounting pressure from economic pressure. The company has NIS 23.0 million of Chief Scientist loans classified as current liabilities. If you strip those out, working capital jumps to NIS 70.4 million and the current ratio rises to 24.45. That tells you the balance sheet is not signaling an immediate liquidity squeeze. But that does not make the liability meaningless. Those loans added another NIS 1.4 million of interest and linkage in 2025, and the company's own sensitivity table shows that a 10% CPI move would cut profit by NIS 2.285 million.

There are also a few practical caveats. Around NIS 7.2 million of cash and securities are pledged to support bank credit at the International Bank. There is also a pledged dollar deposit linked to the Ofek Hadash guarantee, although after the balance sheet date the guarantee expired and the pledge was removed. So the liquidity exists, but not every shekel of it is fully free at all times.

The real point is that the company no longer looks distressed on a survival basis, but it still does not look like a business that can afford to ignore cash flow. This is not a conventional bank-debt story. It is a mix of old state loans, an actively managed securities book, and minority investments that can require more capital from time to time. That is why 2025 has to be read through the whole liquidity stack, not just through the cash line.

Outlook

First finding: 2025 fixed the direction problem, not the quality problem. Moving from a NIS 23.9 million loss to a NIS 7.3 million profit matters, but it still rested mainly on fair value, capital markets and marks.

Second finding: liquidity did not deteriorate the way the headline cash decline suggests. In practice it moved into marketable securities and the managed market book, so the right read is not that the company is running out of cash, but that its liquidity profile has become more market-linked.

Third finding: the portfolio did not broadly heal. A few quoted positions and one major positive thread in Nasus carried much of the improvement, while a meaningful part of the older medtech book still sits below cost.

Fourth finding: the company still has both unrecognized upside and unresolved negative tails. Exithera may one day produce value, but NewMed, Roichman and RPS are reminders that a small investment company does not get to carry too many loose ends without paying for them in the stock.

The obvious conclusion is that 2026 looks like a proof year, not a breakout year. Management says the company will continue to seek attractive investment opportunities, deepen partnerships and help channel capital into portfolio companies. That is directionally fine, but it is too generic. The real tests for the next year are different, whether Capital Point can keep generating realizations without hollowing out its best positions, whether Nasus remains a positive anchor beyond the IPO effect, and whether the liquidity layer stays strong even if capital markets become less forgiving.

That chart matters because it sharpens an easy-to-miss point. Capital Point is not a complete black box. A large share of its financial assets now sits in Level 1, meaning directly observable market prices. At the same time, there are still about NIS 17.3 million in Level 3 if loans to project companies are included, and that is enough to keep fair value judgment as a core audit matter. So the key test for the next year is not whether everything is paper value, but which part of the book is becoming more market-visible and which part is still model-dependent.

In the near term, the market is likely to focus on four things. First, the behavior of the larger quoted holdings, especially Nasus, Aura, Mivtach Shamir and ZIM. Second, the pace of realizations and dividends against the need for follow-on investments. Third, any update in the NewMed dispute or the shareholder-related legal and governance fronts. Fourth, the direction of the dollar and of public markets, because in a company this size one weak market quarter can quickly turn a "reasonable" year into a weak one.

The constructive scenario is easy enough to describe. If Nasus remains stable as a public holding, if local and US markets stay supportive, and if Capital Point keeps realizing positions selectively without losing the spine of the portfolio, the discount to book can narrow. The less comfortable scenario is just as clear, a weaker market backdrop, a legal issue that drags on, or renewed capital needs across the portfolio could quickly bring back doubts about profit quality.

Risks

Fair value is still a sensitive zone

The external auditor singled out fair value estimates of unquoted project companies as a key audit matter. This is not a technical footnote. In a life sciences and technology portfolio, financing rounds, comparables and DCF are not hard numbers. They are valuation ranges. As of year-end 2025, NIS 16.2 million of project investments were classified as Level 3, and another NIS 1.1 million of project-company loans sat in the same layer. That is not most of the company, but it is definitely enough to shape the market's interpretation.

FX, CPI and legacy debt

The company does not hedge its currency or CPI exposures. The sensitivity table shows that a 5% move in the dollar adds around NIS 2.5 million to profit, while a 10% move adds around NIS 5.0 million. On the other side, a 10% CPI increase cuts profit by NIS 2.285 million. So even without conventional financing pressure, there is still meaningful dependence on two macro variables, the dollar and CPI, and they can move reported earnings materially in a company of this size.

Governance and legal overhang

Capital Point is dealing with several legal and governance fronts at once. Roichman is pursuing shareholder oppression claims and monetary relief against the company and office holders, with evidentiary hearings set for May 2026. RPS alleged the existence of a control group and defects in general meeting decisions. NewMed is threatening arbitration over abandonment costs. The company recorded no provisions and believes some of the claims are more likely to fail than succeed, but the market tends to penalize small companies for uncertainty even before a cash loss is booked.

Dilution and follow-on funding risk

The company itself says explicitly that if it cannot participate in follow-on rounds in portfolio companies, it could suffer meaningful dilution. That may be the quietest risk in the whole story. No headline, no arbitration, no lawsuit, just a recurring need to choose which holdings deserve more cash and which ones are allowed to drift away. In an investment company with 19 positions and finite resources, that is a real strategic constraint.

Conclusions

Capital Point is ending 2025 in a meaningfully better place than where it finished 2024. The portfolio recovered, profit came back, the liquidity layer held up, and one new anchor, Nasus, became more visible to the market. The main bottleneck remains the same one, whether the company can turn that value into cash that actually reaches shareholders rather than just into a cleaner fair value line. In the short to medium term, market interpretation will be driven mainly by realizations, the behavior of the quoted holdings, and whether any of the legal or governance tails turns into a real cash event.

Current thesis in one line: Capital Point is no longer mainly a weak-balance-sheet story. It is now a monetization, valuation-quality and shareholder-cash-conversion test.

What changed versus 2024 is that the question is no longer whether the portfolio is still deteriorating, but whether the 2025 recovery is the start of a better cycle or simply one year in which the market helped and the marks worked. The move back to positive earnings, the Nasus IPO and the larger market-linked asset layer push the company forward. At the same time, the fact that profit still lives mostly on fair value, finance income and the market keeps the discount where it is.

The strongest counter-thesis is that the market may be too harsh. One could argue that Capital Point holds a substantial liquid asset layer, does not depend on one single portfolio company, and has already moved a larger part of its value base onto observable market prices rather than just models. If that is the right read, the stock is trading too cheaply relative to the balance sheet.

What could change the market's interpretation in the short to medium term is not another generic line about "identifying opportunities", but more operational proof. Selective realizations, stability or improvement in the larger quoted holdings, no legal surprises, and the ability to preserve liquidity without impairing the quality of the portfolio. That is what could start closing the gap between book value and market value. What could weigh on the stock is the opposite, another year in which the value looks better on paper, while the real cash remains dependent on the next mark, the next sale or the next friendly market window.

Why this matters in one sentence: Capital Point is a clean test of whether a small investment company can turn a recovering portfolio into accessible shareholder cash, or only into NAV that remains trapped inside a discount.

What has to happen over the next 2 to 4 quarters is fairly clear. The company needs continued realizations or dividends without dismantling its strongest positions, it needs Nasus to prove it was more than a one-off 2025 event, and it needs to get through 2026 without being pulled back into capital needs, legal costs or follow-on funding demands that reset the story. What would weaken the thesis is a weaker market quarter, renewed capital requirements in the portfolio, or legal developments that cost more than the market is willing to absorb.